Soluble E-selectin serum levels correlate with disease activity in psoriatic patients

Abstract

E-selectin is an adhesion molecule expressed on vascular endothelial cells in several inflammatory skin diseases, including psoriasis. It is responsible for the adherence between microvascular endothelium and neutrophils, monocytes, eosinophils and subsets of T cells. Soluble E-selectin (sE-selectin) serum levels were measured by ELISA in 32 psoriatic patients before treatment and compared with both post-treatment sE-selectin levels in 16 patients and sE-selectin values in 10 healthy individuals. Soluble E-selectin serum levels were significantly increased in psoriatic patients compared with healthy persons. Moreover, a significant correlation was demonstrated between sE-selectin values and PASI scores. No relationship was found between sE-selectin levels and duration of psoriasis. Soluble E-selectin serum levels decreased significantly after treatment of psoriasis. This phenomenon was more evident in patients with more severe psoriasis. In conclusion, sE-selectin serum levels correlate with the extent of psoriatic lesions and could be used as marker of the disease activity in psoriatic patients.

Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis

“…Numerous reports have correlated the level of disease activity in psoriasis with the levels of soluble vascular adhesion molecules in the sera of patients with psoriasis, in particular soluble E-selectin that is presumably cleaved from the surface of inflamed dermal vessels. [17][18][19][20] Further correlating our animal model with the human condition, we find that serum levels of E-selectin are much higher in K14-VEGF mice (249.42 Ϯ 38.64 ng/mL) than in control mice (37.34 Ϯ 7.06 ng/mL), and, just as important, these increased levels are reduced with VEGF Trap treatment (to 96.74 Ϯ 16.25 ng/mL). Altogether, our data indicate that VEGF is continuously required to maintain the psoriasiform lesions in older K14-VEGF mice and that even longstanding disease can be dramatically reversed with VEGF blockade.…”

“…[14][15][16] In addition, the levels of soluble adhesion molecules in the sera of psoriasis patients, particularly E-selectin, provide a valuable surrogate marker of disease severity and therapeutic efficacy of various treatments. [17][18][19][20] Despite this, most efforts at understanding the etiology of this disease have focused on the epidermal and inflammatory aberrations. In the abnormally thickened epidermis, the top layer (termed stratum corneum), usually consisting of cornified keratinocytes lacking nuclei, instead contains cells with nuclei (termed parakeratosis).…”

Targeting selectins and selectin ligands in inflammation and cancer

“…Soluble forms of E-selectin have been detected in supernatants of cytokine-activated endothelial cells [125] and are elevated in serum of subjects with bronchial asthma [126,127], eczema [128], psoriasis [129][130][131], atopic and allergic dermatitis [131][132][133][134][135], Kawasaki disease [136], Guillain-Barre syndrome [137] or Graves disease [138] compared with normal subjects. Soluble E-selectin is deficient in mice null for PSGL-1, suggesting a role for PSGL-1 in solubilization [139].…”

Gene expression profiling in psoriatic scalp hair follicles: clobetasol propionate shampoo 0.05% normalizes psoriasis disease markers

“…13,14 Recently identified new markers include genes involved in the Wnt pathway, disease-related cytokines and chemokines. [15][16][17] Changes in the expression level of disease-related gene were correlated with stages of disease progression and clinical severity scores, [18][19][20][21][22][23] allowing them to be used for examining the effects of treatments. As examples, therapeutic antibodies against tumour necrosis factor alpha and interferon gamma, as well as the immune-modulatory drug pimecrolimus, were shown to be effective in treating psoriasis.…”